 |
|
|
| |
INTERIM ANALYSIS OF A 3-YEAR FOLLOW-UP STUDY OF NS5A AND NS3 RESISTANCE-ASSOCIATED VARIANTS AFTER TREATMENT WITH GRAZOPREVIR-CONTAINING REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
|
| |
| |
Reported by Jules Levin
AASLD 2026 Nov 11-15 Boston, MA
Frederick Lahser, Angela Galloway, Peggy Hwang, John Palcza, Janice Wahl, Michael Robertson, Eliav Barr, Todd Black, Ernest Asante-Appiah, Barbara Haber
Merck & Co., Inc. Kenilworth, NJ, USA
|
| |
|
|
|
|
|
